|Bid||112.67 x 1200|
|Ask||113.41 x 1100|
|Day's range||112.68 - 113.86|
|52-week range||82.77 - 122.15|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||28.25|
|Earnings date||20 May 2020|
|Forward dividend & yield||2.16 (1.90%)|
|Ex-dividend date||25 Dec 2019|
|1y target est||126.39|
Medtronic is the latest company to announce a potential impact to its financial results from the outbreak which has disrupted supply chains and delayed reopening of factories in China. Although its manufacturing operations in the country were up and running, Medtronic expects a negative impact from a slowdown in medical device procedures in the region. "Given the fluidity of this situation, the duration and magnitude of the impact are difficult to quantify at this time," Chief Executive Officer Omar Ishrak said on a conference call.
Investing.com - Medtronic reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Medtronic (MDT) to integrate Digital Surgery's business within its Surgical Robotics arm, in turn augmenting the company's position in the field of surgical AI.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But in our...
With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.
Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.
Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.